BioArctic AB (publ) BRCTF
30.33 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
30.32 Day range 30.33
27.82 52-week range 38.75
- YTD
- -12.69%
- 1 year
- -5.69%
News
prnewswire.com BioArctic collaborator Novartis terminates agreement STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option,…
prnewswire.com BioArctic's Nomination Committee appointed STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The…
prnewswire.com Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to…
seekingalpha.com BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript
prnewswire.com BioArctic and Mesenkia enter oncology research collaboration STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration agreement…
prnewswire.com Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026, at 8:00…
prnewswire.com More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER)…
prnewswire.com BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology STOCKHOLM, June 22, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and…
prnewswire.com Number of shares and votes in BioArctic AB (publ) as of May 29, 2026 STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants…
prnewswire.com Bulletin from the Annual General Meeting in BioArctic AB (publ) STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of…
seekingalpha.com BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call Transcript
prnewswire.com BioArctic Interim Report for the period January - March 2026 STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted…
prnewswire.com Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET STOCKHOLM, May 13, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's first quarter report for January - March 2026 on Wednesday, May 20, 2026, at 8:00…
prnewswire.com Number of shares and votes in BioArctic AB (publ) as of February 27, 2026 STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to…
seekingalpha.com BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript BioArctic AB (publ) (BRCTF) Q4 2025 Earnings Call Transcript
prnewswire.com BioArctic Interim Report for the period October - December 2025 STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai…
prnewswire.com Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET STOCKHOLM, Feb. 11, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's fourth quarter report for October - December 2025 on Wednesday, February 18, 2026,…
prnewswire.com Leqembi included in China's commercial insurance innovative drug list STOCKHOLM , Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance…
prnewswire.com New data on lecanemab to be presented at CTAD conference STOCKHOLM , Nov. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's…
prnewswire.com Leqembi® approved for IV maintenance treatment in the United Kingdom STOCKHOLM , Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks…